Vesence | $9,000,000 | (Oct 30, 2025)
Sparrow BioAcoustics | $10,000,000 | (Oct 30, 2025)
Reflectiz | $22,000,000 | (Oct 30, 2025)
Allorion Therapeutics
United States
- Natick, Massachusetts
- 13/03/2023
- Series B
- $50,000,000
At Allorion Therapeutics, we focus on developing novel small molecule drugs against cancer and autoimmune diseases. Our team is comprised of experts in cancer biology and drug development. The fields we want to dive into include:
• selecting well-validated targets with clear clinic development routes and discovering their modulators with distinct mechanisms of actions
• building our innovative data and screening platforms for sustainable success
• constructing chemical libraries with priorities on allosteric and covalent modulators and optimizing the libraries through the aid of AI
Allorion has dual sites operating in Natick, Massachusetts and Guangzhou, China.
- Industry Pharmaceutical Manufacturing
- Website https://www.alloriontx.com/
- LinkedIn https://www.linkedin.com/company/alloriontx/
Related People
Fang LiCo Founder
United States -
Cambridge, Massachusetts,
I am a research professional working in the pharmaceutical industry. I have extensive oncology and immuno-oncology experience from target ID/validation, lead discovery and optimization to translational research and early-phase clinical trials.
I lead cross-functional teams with diverse expertise, ranging from cancer biology and computational biology to clinical assay development. I am skilled at building collaborations with CROs and investigators in academia resulting in clinical trials and high impact publications.
Mem0 | $24,000,000 | (Oct 30, 2025)
Valthos | $30,000,000 | (Oct 30, 2025)
Mondra | $13,206,500 | (Oct 30, 2025)
hoop.dev | Undisclosed Amount | (Oct 30, 2025)
IORGANBIO | $2,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)
Homecourt | $8,000,000 | (Oct 30, 2025)
VentureMed Inc. | $28,000,000 | (Oct 30, 2025)
Recess | $30,000,000 | (Oct 30, 2025)